Insulin isophane human/insulin regular human

Drug Overview

In the clinical specialty of Endocrinology, achieving a balance between immediate glycemic control and sustained basal coverage is a fundamental therapeutic goal. Insulin isophane human/insulin regular human (commonly marketed as Humulin 70/30 or Novolin 70/30) is a foundational pharmaceutical intervention belonging to the Mixed Insulin drug class. It is a biphasic suspension consisting of 70% Insulin Isophane (NPH) and 30% Insulin Regular.

As a high-efficiency Targeted Therapy, this medication serves as a vital Hormone Replacement Therapy for individuals with Diabetes Mellitus. It is specifically engineered to provide a “two-in-one” solution: the Regular component addresses the glucose spike following a meal, while the Isophane (NPH) component provides intermediate-acting background coverage. This formulation is often preferred for its cost-effectiveness and the ability to reduce the total number of daily injections.

• Generic Name: Insulin Isophane Human and Insulin Regular Human (rDNA origin)
• US Brand Names: Humulin 70/30, Novolin 70/30, ReliOn 70/30
• Drug Class: Mixed Insulin (Intermediate-acting + Short-acting)
• Drug Category: Endocrinology / Antidiabetic Agents / Metabolic Modulators
• Route of Administration: Subcutaneous injection
• FDA Approval Status: FDA-approved (1982/1983) as a biosynthetic human insulin formulation.
  
  Humulin 70/30 and Novolin 70/30 are mixed insulins offering comprehensive blood sugar control. Rely on our experienced diabetes care specialists. insulin isophane human/insulin regular human

What Is It and How Does It Work? (Mechanism of Action)

To understand how 70/30 Mixed Insulin functions, one must examine the distinct kinetic profiles of its two components. Because it is a “human” insulin (rather than an analog), its onset and duration are governed by the physical state of the insulin molecules in the suspension.

1. The Short-Acting Phase (30% Regular Human Insulin)

This is the soluble, clear portion of the mixture.

• Molecular Action: Upon injection, these insulin molecules are already in a state ready for absorption.
• Prandial Coverage: It begins working within 30 to 60 minutes, helping the body process carbohydrates from the meal consumed immediately after the injection. It triggers GLUT4 translocation to pull glucose into muscle and fat cells.

2. The Intermediate-Acting Phase (70% Isophane/NPH)

This is the “cloudy” portion of the mixture, modified with protamine and zinc.

• Crystalline Depot: The addition of protamine creates crystals that do not dissolve instantly in the subcutaneous tissue.
• Basal Control: These crystals dissolve slowly over several hours, providing a steady release of insulin that mimics a “background” supply. This suppresses hepatic gluconeogenesis (the liver’s production of sugar) between meals and during the night.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Humulin 70/30 / Novolin 70/30 is the improvement of glycemic control in adults and pediatric patients with Diabetes Mellitus (Type 1 and Type 2). It is particularly utilized in Type 2 Diabetes for patients who require a simplified regimen.

Other Approved & Off-Label Uses

Within the sophisticated 2026 landscape of Endocrinology:

• Regimen Simplification: Indicated for patients who find the “basal-bolus” regimen (using separate pens for different insulin types) too complex or difficult for adherence.
• Gestational Diabetes: Frequently utilized in pregnancy due to its long-standing safety record and the fact that human insulin does not cross the placenta.
• Primary Endocrinology Indications:
  • Hormone Replacement Therapy for absolute or relative insulin deficiency.
  • Reduction of HbA1c in patients with high fasting and post-meal glucose variability.
  • Stabilization of the Hypothalamic-Pituitary-Adrenal (HPA) Axis by preventing the metabolic stress of severe hyperglycemia.

Dosage and Administration Protocols

Dosing is highly individualized and is typically administered twice daily (30 to 60 minutes before breakfast and dinner).

Export to Sheets

Specialized Administration Protocols

• The Resuspension Process (Mandatory): Because this is a suspension, the NPH crystals settle at the bottom. Before every dose, the patient must roll the vial/pen 10 times and invert it 10 times. The liquid must appear uniformly cloudy. Failure to mix results in an incorrect ratio of insulin, leading to unpredictable blood sugar.
• The “Lead Time”: Unlike rapid-acting analogs, this human insulin requires a 30-minute “waiting period” before eating to prevent a post-meal spike.
• Site Rotation: Essential to rotate injection sites (abdomen, thigh, or upper arm) to prevent Lipodystrophy (fatty lumps), which can impair insulin absorption.

Clinical Efficacy and Research Results

Clinical data through 2026 confirms that human insulin mixtures remain a cornerstone of global diabetes care, particularly where cost and accessibility are primary concerns.

Numerical Data and Results

• Onset of Action: 30 to 90 minutes.
• Peak Effect: Dual peaks—a smaller peak at 2–4 hours (Regular) and a broader peak at 6–12 hours (NPH).
• Duration of Action: Approximately 18 to 24 hours.
• HbA1c Impact: Research results show that twice-daily 70/30 mixtures can achieve a mean HbA1c reduction of 0.8% to 1.2% in Type 2 patients failing oral agents.
• Predictability: Data highlights that while analogs are faster, 70/30 human mixtures provide a very predictable “mid-day” peak that can be useful for patients who eat a mid-afternoon snack.

Safety Profile and Side Effects

The primary safety concern with 70/30 Mixed Insulin is Hypoglycemia (Low Blood Sugar), especially during the broad peak of the NPH component.

Common Side Effects (>10%)

• Hypoglycemia: Symptoms include shakiness, sweating, confusion, palpitations, and intense hunger.
• Weight Gain: A common metabolic effect as glucose is moved into cells for storage rather than being excreted.
• Injection Site Reactions: Redness, itching, or localized swelling.

Serious Adverse Events

• Severe Hypoglycemia: May lead to seizures or loss of consciousness; requires immediate treatment with glucose or Glucagon.
• Hypokalemia: Insulin shifts potassium into cells; monitoring is required in patients on diuretics or those with heart rhythm issues.
• Lipohypertrophy: Skin thickening from repeated injections in the same spot, making insulin absorption erratic.
• Anaphylaxis: Rare but serious systemic allergic reactions to human insulin or protamine.

Research Areas (2024–2026)

Direct Clinical Connections

Active research in 2026 is investigating the drug’s impact on Pancreatic Beta-cell Preservation. Emerging evidence suggests that “Early Intensive Insulin Therapy” using biphasic mixtures can reduce the “glucotoxic” load on the pancreas in newly diagnosed Type 2 patients, potentially allowing their remaining beta cells to function longer.

Generalization and Advancements

The field is moving toward advancements in Novel Delivery Systems, such as “Smart Pens” for 70/30 insulin that can track if the pen was properly rolled and inverted before the dose. There is also interest in Osteoblast/Osteoclast Activity, as researchers evaluate how the steady insulin levels provided by 70/30 mixtures influence bone mineralization in pediatric populations with Type 1 Diabetes.

Disclaimer: This information should be considered exploratory unless supported by definitive clinical evidence. While it represents significant frontiers in medical research, it is not yet applicable to all clinical scenarios or standard of care protocols. 

Patient Management and Clinical Protocols

Monitoring and Precautions

• Vigilance: Patients must be educated on the 30-minute lead time. Injecting and eating immediately will result in high blood sugar followed by a “crash” hours later.
• Lifestyle: Medical Nutrition Therapy (MNT) focusing on consistent carbohydrate intake is mandatory. Because the ratio of NPH to Regular is fixed, the patient cannot easily “adjust” for a larger-than-normal meal.
• Sick Day Rules: Insulin needs often increase during illness; blood sugar should be checked every 2–4 hours.

Do’s and Don’ts

• DO ensure the insulin is milky/cloudy after mixing.
• DO check your blood sugar before every injection.
• DON’T use the insulin if it contains clumps or “frosting” on the glass that does not disappear after rolling.
• DON’T mix this insulin with any other insulin in the same syringe.
• DON’T use 70/30 mixed insulin in an insulin pump or for intravenous (IV) use.

Legal Disclaimer

This document is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. 70/30 Mixed Insulin must be used under the supervision of a licensed healthcare professional. Dosing errors with insulin can be fatal.